Anti-cancer Drug Raw Powder Dasatinib CAS: 302962-49-8 High Purity Pharmaceutica

Basic Information:

nombre del producto: Dasatinib
Sinónimos: Dasatinib(BMS-354825);BMS-354825;NORTE-[2-Chloro-6-methylphenyl]-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]aminado]-5-thiazolecarboxamide;5-Thiazolecarboxamide, NORTE-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]aminado]-;Dasatinib;NORTE-(2-Chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]aminado]-1,3-thiazole-5-carboxamide;NORTE-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide;2-{6-[4-(2-HYDROXY-ETHYL)-PIPERAZIN-1-YL]-2-METHYL-PYRIMIDIN-4-YLAMINO}-THIAZOLE-5-CARBOXYLIC ACID (2-CHLORO-6-METHYL-PHENYL)-AMIDE
CASO: 302962-49-8
MF: C22H28ClN7O3S
MW: 488.01
EINECS: 1806241-263-5
Punto de fusion: 275-286° C
Temperatura de almacenamiento: -20° C Congelador
Apariencia: White solid

Uso:

Leukemia drug Dasatinib is an oral potent oncogenic kinase inhibitor, which can block signal of cancer cell replication acceleration , in May 2009, the US Food and Drug Administration (FDA) formally approved the sale of dasatinib , It has been clinically used for the treatment of various chronic myeloid leukemia (CML), including treatment of chronic myeloid leukemia which is resistant or intolerant to the treating programs including imatinib mesylate., Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph + ALL) and the treatment of patients with solid tumors.

October 28, 2010 ,the FDA approved dasatinib (Sprycel) of the new indication which is used for the treatment of the rare leukemia first diagnosed Philadelphia chromosome-positive called chronic myeloid leukemia (Ph + CP-CML) . The disease is a blood and bone marrow disease associated with genetic abnormality .

An open-label randomized clinical trial conducted in patients with CP-CML evaluated the safety and efficacy of dasatinib . Common side effects include decreased activity of the bone marrow caused by red blood cells, white blood cells and platelets decreased (myelosuppression), fluid retention, diarrhea, dolor de cabeza, musculoskeletal pain, and rash.

October 11, 2011, the US Food and Drug Administration (FDA) said the leukemia drug dasatinib (Sprycel, Bristol-Myers Squibb Company) might increase pulmonary arterial hypertension (PAH) risk. Pulmonary hypertension is a rare but serious disease that can lead to the condition that heart pumping blood to the lungs becomes more difficult by raising the pressure . PAH symptoms include shortness of breath, fatigue, swelling of the legs and ankles, clinicians must differentiate these symptoms from other similar symptoms.

Since 2006 Dasatinib was approved in the US market ,there had been 12 associated pulmonary hypertension events ,pulmonary hypertension symptoms included shortness of breath, fatigue, hypoxia and fluid retention, patients then were confirmed pulmonary hypertension by the results of right heart catheterization ,studies have shown that the biggest cause of the disease may come from patients taking dasatinib.

Nuestro servicio

1.100% La política de reenvío es nuestro negocio básico. Reenvío del 100% inmediatamente si su paquete permanece en Aduana por 4 días y no se actualiza.
2.Reembolso total por 15 días de insatisfacción con la calidad.
3.Podemos proporcionar muestras gratis..
4.Tenemos un embalaje especial ,Se puede pasar fácilmente por la aduana.Será más seguro..
5.Nuestra empresa tiene una cooperación a largo plazo con DHL.EMS.Fedex y así sucesivamente. Se puede enviar a su mano más rápidamente. La foto del paquete debe ofrecerse dentro de las 12 horas posteriores a la recepción de su pago de esteroides.
6.Si tienes la oportunidad de venir a China. Puedo mostrarte nuestro laboratorio.
7.Nuestra empresa tiene WU, MG, TT, y formas de pago de Bitcoin por adelantado. 95% por el costo de los péptidos al principio por pedido, el resto nos lo puede ofrecer en su próximo pedido;